1.60
+0.07(+4.58%)
Currency In USD
| Previous Close | 1.53 |
| Open | 1.51 |
| Day High | 1.62 |
| Day Low | 1.45 |
| 52-Week High | 15.85 |
| 52-Week Low | 1.1 |
| Volume | 1.01M |
| Average Volume | 831,484 |
| Market Cap | 98.22M |
| PE | -0.47 |
| EPS | -3.38 |
| Moving Average 50 Days | 1.6 |
| Moving Average 200 Days | 2.13 |
| Change | 0.07 |
If you invested $1000 in Pliant Therapeutics, Inc. (PLRX) since IPO date, it would be worth $75.12 as of November 10, 2025 at a share price of $1.6. Whereas If you bought $1000 worth of Pliant Therapeutics, Inc. (PLRX) shares 3 years ago, it would be worth $78.05 as of November 10, 2025 at a share price of $1.6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pliant Therapeutics Provides Update on BEACON-IPF
GlobeNewswire Inc.
Jun 27, 2025 8:05 PM GMT
Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutic
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
GlobeNewswire Inc.
May 21, 2025 8:03 PM GMT
SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as part of the American Thoracic So
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
GlobeNewswire Inc.
May 01, 2025 8:05 PM GMT
- Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials - Pliant will reduce its current workforce by approximately 45% - Closing activities for BEACON-IPF trial ongoing; topline data expected